Co-Authors
This is a "connection" page, showing publications co-authored by Cristina Mussini and Andrea Antinori.
Connection Strength
1.657
-
Development and validation of a prediction model for tocilizumab failure in hospitalized patients with SARS-CoV-2 infection. PLoS One. 2021; 16(2):e0247275.
Score: 0.233
-
Evidence-based renewal of the Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. New Microbiol. 2018 10; 41(4):247-255.
Score: 0.197
-
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study. BMC Med. 2018 05 29; 16(1):79.
Score: 0.192
-
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2016. New Microbiol. 2017 Apr; 40(2):86-98.
Score: 0.178
-
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. Lancet HIV. 2015 Mar; 2(3):e98-106.
Score: 0.153
-
Disentangling the Association of Hydroxychloroquine Treatment with Mortality in Covid-19 Hospitalized Patients through Hierarchical Clustering. J Healthc Eng. 2021; 2021:5556207.
Score: 0.060
-
Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study. Front Med (Lausanne). 2021; 8:639970.
Score: 0.059
-
Heparin in COVID-19 Patients Is Associated with Reduced In-Hospital Mortality: The Multicenter Italian CORIST Study. Thromb Haemost. 2021 Aug; 121(8):1054-1065.
Score: 0.058
-
Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study. Nutr Metab Cardiovasc Dis. 2020 10 30; 30(11):1899-1913.
Score: 0.056
-
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL. J Antimicrob Chemother. 2019 09 01; 74(9):2732-2741.
Score: 0.053
-
Genetic divergence of HIV-1 B subtype in Italy over the years 2003-2016 and impact on CTL escape prevalence. Sci Rep. 2018 10 24; 8(1):15739.
Score: 0.049
-
Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment. J Clin Virol. 2018 07; 104:61-64.
Score: 0.048
-
Managing the long surviving HIV patient: a proposal for a multidimensional first-level diagnostic assessment. New Microbiol. 2018 Apr; 41(2):112-117.
Score: 0.048
-
Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort. HIV Clin Trials. 2018 04; 19(2):52-60.
Score: 0.047
-
Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice. Antivir Ther. 2018; 23(3):249-257.
Score: 0.047
-
Brief Report: Drop in CD4+ Counts Below 200 Cells/µL After Reaching (or Starting From) Values Higher than 350 Cells/µL in HIV-Infected Patients With Virological Suppression. J Acquir Immune Defic Syndr. 2017 12 01; 76(4):417-422.
Score: 0.047
-
Comparative Evaluation of Subtyping Tools for Surveillance of Newly Emerging HIV-1 Strains. J Clin Microbiol. 2017 09; 55(9):2827-2837.
Score: 0.045
-
Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort. PLoS One. 2017; 12(5):e0177402.
Score: 0.045
-
Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients. PLoS One. 2017; 12(2):e0171611.
Score: 0.044